Management of Elevated LDL-C on Maximum-Dose Rosuvastatin

Current Treatment Assessment

For adults aged 40-75 years, moderate-intensity statin therapy is the baseline recommendation for primary prevention, according to the American Diabetes Association 2, 3
The American College of Cardiology recommends that patients with very high baseline LDL-C levels warrant immediate combination therapy rather than sequential monotherapy trials 1

The International Lipid Expert Panel recommends immediate addition of ezetimibe when baseline LDL-C levels remain very high on maximum statin therapy, providing an additional 15-25% reduction in LDL-C 1
Adding ezetimibe 10 mg daily to rosuvastatin 40 mg will provide a combined LDL-C reduction of approximately 60-75% from baseline, with a safety profile similar to statin monotherapy 1

The American College of Cardiology recommends evaluating for statin-associated side effects that might limit adherence, such as muscle pain or liver enzyme elevations 1
With an LDL-C of 202 mg/dL in a 45-year-old, consider screening for familial hypercholesterolemia (FH), as this may require specialized management 1
Therapeutic lifestyle changes, including a diet with <7% of total calories as saturated fat and <200 mg cholesterol per day, regular physical activity, and weight management if BMI ≥25 kg/m², are recommended by the American Heart Association 5, 1

Obtain lipid panel in 4-6 weeks, monitor hepatic transaminases (AST/ALT) as recommended for statin therapy, assess for muscle symptoms at each visit, and continue annual lipid monitoring once LDL-C goal is achieved 2, 1, 4